UCB Ventures
Venture capitalBrussels · Seed–Series A · 5 people tracked
Investment thesis
UCB Ventures is a €150 million corporate venture fund established in 2017 that invests in early-stage therapeutics and technology platforms in neurology, neurodegenerative diseases, immunology, and musculoskeletal/bone health. The fund focuses on innovative companies adjacent to or outside UCB's core therapeutic areas.
Team · 5 people
from public directoriesWhat they invest in
from 2 of 2 portfolio companiesBiotech ×2Deep Tech ×2AI & Machine Learning ×1Healthtech ×1Medical Devices ×1
HQs:United States×1
Investments · 2 tracked
founders shown can be your intro pathIris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles.
BiotechDeep TechHealthtech
Megan Matthews(Co-founder & President)
Switch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Kevin Zhang(Director)Dylan Morris(Director)Si-Ping Han(Secretary)Deepshikha Datta(Chief Executive Officer and President)
Board seatAlicia Irurzun-Lafitte· per SEC Form D · $36M raise · filed Nov 2022
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does UCB Ventures invest at?
- UCB Ventures invests at the Seed, Series A stages.
- What sectors does UCB Ventures focus on?
- UCB Ventures focuses on Biotech, Medical Devices.
- Where is UCB Ventures located?
- UCB Ventures is headquartered in Brussels, BE.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.